Searched for
SARABJIT KOUR NANGRA
HCL, Infosys, TechM good stocks to buy for long-term investors: Nangra"We're recommending largecap companies like HCL, Infosys, at these valuations."- Cipla surges over 6% despite weak Q2 numbersThe company said total revenues for the quarter increased 8.6 per cent on a YoY basis to Rs 3,671.88 crore from Rs 3,379.35 crore reported ...
- We have buy call on Sun Pharma, Ranbaxy: Sarabjit Kour Nangra, Angel BrokingLupin is correcting to realistic levels
- 8 firms buck the trend, manage stellar third-quarter earningsThird-quarter earnings have been dismal for most of the companies. But eight firms managed to forge ahead due to strong management and soli...
- Despite warning letter, Ipca Lab still a top return generator: Sarabjit Kour Nangra, Angel BrokingIn a chat with ET Now, Sarabjit Kour Nangra, Angel Broking, says since Ipca was already under import alert, the warning letter now means th...
- Neutral rating on Cipla, Sun Pharma no game changer: Sarabjit Kour Nangra, Angel Broking, Pharma"ANDA approval will add to the company but since the company is so big that such small approvals do not add significantly."
- Infosys' topline a positive surprise; revenue growth commendable: Sarabjit Kour Nangra, Angel Broking"They have not given any idea on their guidance for the full year so far, but I guess the way they have been doing, they should be able to ...
- Tech Mahindra and many small caps have indicated trend of lower revenue for Q1: Sarabjit Kour Nangra, Angel Broking"Most of the IT companies have been pointing towards a healthy (revenue filled) full year, which should entail a healthy first quarter."
- Most of large-cap pharma stocks are pretty balanced in terms of valuation: Sarabjit Kour Nangra, Angel BrokingI believe the overall stock reaction today is in view of the same. Secondly, Sun Pharma management has refrained from giving any guidance f...
- Lupin shares fall over 3% on disappointing Q4 earningsThe stock ended 3.35 per cent lower at Rs 1,690.60 on the BSE. During the day, it slipped 3.95 per cent to Rs 1,680.
- Infosys guidance a sure sign that they mean business: Sarabjit Kour Nangra, Angel BrokingThey have been guiding again and again that FY17 onwards, they expect Infosys to be back being the bellwether company in terms of the IT se...
- Infosys PAT higher than our expectations: Sarabjit Kour Nangra, Angel Broking"Sales are in line, as you said, and definitely even PAT is higher than our expectations."
- IPCA Laboratories stock slumps 16 per centShares of IPCA Laboratories slumped nearly 16 per cent to hit its 52-week low in early trade amid reports of stock downgrade.
- Sun Pharma shares fall over 2%; slip for second day in a row on US FDA concernsThe stock has fallen on reports that Halol plant in Gujarat has been subjected to surprise inspection by the American drug regulator USFDA.
- Sun Pharma shares dip on surprise audit by Food and Drug Administration at Halol plantAt the NSE, the stock lost 4.29 per cent to Rs 821. The stock was the biggest loser among the blue-chips on both Sensex and Nifty.
- Sun Pharma falls 6% as USFDA inspects Halol unit; facility contributes 40% of US salesThe facility is important for the company as its contributes to around 40 per cent of US sales and around 25 per cent of consolidated profi...
- Ranbaxy shares settle 1.51 per cent down; market capitalisation erodes by Rs 43 croreShares of Ranbaxy Laboratories today settled for the day with losses of 1.51 %, pursuant to which the market capitalisation eroded by Rs 43...
- Ranbaxy, Teva settle claims with New York Attorney General; stock ralliesShares of Ranbaxy Laboratories gained momentum after the company along with Teva Pharma agreed to settle a probe by the New York Attorney G...
- Expect robust numbers for Ranbaxy: Sarabjit Kour Nangra, Angel BrokingIn an interview with ET Now, Sarabjit Kour Nangra, VP–Research-Pharma, Angel Broking, shares her views on some pharma stocks. Excerpts:
- Expect 18% top line growth for Lupin in Q2: Sarabjit Kour Nangra, Angel BrokingIn an interview with ET Now, Sarabjit Kour Nangra, VP–Research: Pharma, Angel Broking, gives her views on Lupin’s expected earnings. Excerp...
Load More
